Nature Reviews Neuroscience - Rapid-acting antidepressant interventions, such as ketamine and psilocybin, are thought to enhance neural plasticity. This Review outlines evidence of synaptic...

Ibogaine — a psychoactive plant derivative — has attracted attention for its anti-addictive and anti-depressant properties. But ibogaine is a finite resource, extracted from plants native to Africa like the iboga shrub (Tabernanthe iboga) and the small-fruited…

A single dose of psilocybin significantly increased emotional empathy in depressed individuals for up to two weeks.

MDMA-assisted therapy as a treatment for major depressive disorder: proof of principle study - Volume 227 Issue 5

A treatment for depression involving just two doses of psilocybin may have effects that last for years. A new follow-up study found that two-thirds of participants were still in remission five years after their therapy, pointing to its potential durability.

While clinical trials investigate psychedelics for addiction treatment, new population-level research indicates that LSD is associated with reduced alcohol use disorder in naturalistic settings.

UC Davis researchers have developed a new method that uses light to transform amino acids — the building blocks of proteins — into molecules that are similar in structure to psychedelics and mimic their interaction with the brain. Like psychedelics, these…

Participants took 25mg of psilocybin, reporting deeper psychological insight and better wellbeing a month later

Northeastern researchers examine how the psychedelic Mescaline drug affects the brain using MRI imaging and lab testing.

UC Davis researchers have stripped down LSD to the base features responsible for its hallucinogenic and therapeutic effects.